TrialBlood advances2026

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Maria V D Soares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.